Laufs V, et al. - The predictive role of excision repair cross complementing group 1 (ERCC1) with the new specific antibody in a larger series of adrenocortical carcinoma (ACC) was assessed. No direct association was demonstrated between ERCC1 expression with sensitivity to platinum-based chemotherapy (PBC) in ACC. Therefore, in patients with ACC, other predictive biomarkers are required to support treatment decisions.